52U Stock Chart & Stats
€5.74
-€0.14(-2.41%)
At close: 4:00 PM EST
€5.74
-€0.14(-2.41%)
Day’s Range― - ―
52-Week Range€4.34 - €8.14
Previous CloseN/A
Volume0.00
Average Volume (3M)83.00
Market Cap
€126.56M
Enterprise Value€165.61M
Total Cash (Recent Filing)€24.15M
Total Debt (Recent Filing)€1.81M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding28,000,374
10 Day Avg. Volume0
30 Day Avg. Volume83
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hyloris Pharmaceuticals SA News
52U FAQ
What was Hyloris Pharmaceuticals SA’s price range in the past 12 months?
Hyloris Pharmaceuticals SA lowest stock price was €4.34 and its highest was €8.14 in the past 12 months.
What is Hyloris Pharmaceuticals SA’s market cap?
Hyloris Pharmaceuticals SA’s market cap is €126.56M.
When is Hyloris Pharmaceuticals SA’s upcoming earnings report date?
Hyloris Pharmaceuticals SA’s upcoming earnings report date is Sep 24, 2026 which is in 79 days.
How were Hyloris Pharmaceuticals SA’s earnings last quarter?
Hyloris Pharmaceuticals SA released its earnings results on Mar 26, 2026. The company reported -€0.099 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.099.
Is Hyloris Pharmaceuticals SA overvalued?
According to Wall Street analysts Hyloris Pharmaceuticals SA’s price is currently Overvalued.
Does Hyloris Pharmaceuticals SA pay dividends?
Hyloris Pharmaceuticals SA does not currently pay dividends.
What is Hyloris Pharmaceuticals SA’s EPS estimate?
Hyloris Pharmaceuticals SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hyloris Pharmaceuticals SA have?
Hyloris Pharmaceuticals SA has 28,000,374 shares outstanding.
What happened to Hyloris Pharmaceuticals SA’s price movement after its last earnings report?
Hyloris Pharmaceuticals SA reported an EPS of -€0.099 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.724%.
Which hedge fund is a major shareholder of Hyloris Pharmaceuticals SA?
Currently, no hedge funds are holding shares in DE:52U
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease. Beyond this, Hyloris addresses a diverse range of other ailments, including post-operative pain management, dental indications, severe and recurring vulvovaginal candidiasis, specific cancers (like acute myeloid leukemia and small cell lung cancer), interstitial cystitis/painful bladder syndrome (IC/PBS), attention deficit hyperactivity disorder (ADHD), and various viral infections. Established in 2012, Hyloris Pharmaceuticals SA is headquartered in Liège, Belgium.
Technical Analysis
Options Prices
Currently, No data available
---